Characteristics and prognosis of malignant disease of the breast in women of very low age

Czech version

Authors: D. Kolařík ¹; V. Pecha ²; P. Křepelka ¹; M. Hasilová ¹; F. Hron ¹; L. Krofta ¹; B. Sehnal ³; M. Prudilová ²; M. Trnková ⁴; H. Kolářová ⁵
Authors‘ workplace: Ústav pro péči o matku a dítě, Praha, ředitel doc. MUDr. J. Feyereisl, CSc. ¹; Medicon Praha, s. r. o., Praha, primář MUDr. V. Pecha ²; Gynekologicko-porodnická klinika 1. LF UK a FN Na Bulovce, Praha, přednosta prof. MUDr. M. Halaška, DrSc. ³; Biolab Praha, Praha, ředitelka MUDr. M. Trnková ⁴; Ústav aplikované matematiky a informačních technologií, Praha ⁵
Published in: Ceska Gynekol 2011; 76(6): 457-462
Category: Original Article

Overview

Objective:
This study aims to describe characteristics of malignant diseases of the breast in women of very low age (thus with breast cancer diagnosed before 35^th year of age) and compare those characteristics with the phenotype of “average” breast cancer in Czech female population.

Methods:
98 women diagnosed with breast cancer before the age of 35 and treated between 2001 and 2010 in private medical center Medicon Praha s.r.o. were enrolled to this retrospective study. The control group of 100 women was constituted by random choice from patients older than 35 years at the time of diagnosis treated in the same time period.

Results:
Size of the tumors at presentation were similar in both study groups. Tumors in younger group exhibited higher proliferative activity, higher grade and lower count of estrogen receptors. On the contrary, in the group of older women was significantly higher percentage of lobular type of cancer and also the proportion of in situ carcinomas. The number of multifocal tumors, positivity of HER-2/neu and progesterone receptors were all without statistically significant difference. In younger women neoadjuvant chemotherapy has been used more frequently. Prognosis of the disease did not differ in both groups.

Conclusion:
Tumors diagnosed in women younger than 35 years can be considered more aggressive. However, using adequate treatment makes the prognosis comparable in both age groups.

Key words:
breast cancer, very young age, characteristics of the cancer, prognosis.

Sources

1. AJCC Cancer Staging Manual, 6^th ed. Philadelphia: Lippincott Raven, 2002.

2. Mezinárodní klasifikace nemocí pro onkologii. Česká verze, 3. ed. Praha: UZIS, 2004.

3. UICC (International Union Against Cancer): TNM classification of malignant tumours, 7^th ed. Oxford: Willey-Blackwell, 2009.

4. Projekt EVA 35. http://www.medical-services.cz/Publishing/ Projekt-EVA-35/

5. Aryandono, T., Harijadi, S. Breast cancer in young women: prognostic factors and clinicopathological features. Asian Pac J Cancer Prev, 2006, 7, p. 451-454.

6. Bonnier, P., Romain, S., Charpin, C., et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer, 1995, 62, p. 138-144.

7. Cancello, G., Maisonneuve, P., Rotmensz, N., et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol, 2010, 21, p. 1974-1981.

8. Chan, JK., Wong, CS. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv Anat Pathol, 2001, 8, p. 165-172.

9. Chung, M., Chang, HR., Bland, KI., Wanebo, HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer, 1996, 77, p. 97-103.

10. Cibula, D., Petruzelka, L. Onkogynekologie. Praha: Grada Publishing, 2009.

11. Colleoni, M., Rotmensz, N., Robertson, C., et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol, 2002, 13, p. 273-279.

12. de la Rochefordiere, A., Asselain, B., Campana, F., et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet, 1993, 341, p. 1039-1043.

13. Driak, D., Dvorska, M., Svandova, L., et al. Changes in expression of some apoptotic markers in different types of human endometrium. Fol Biol, in press.

14. Dušek, L., Žaloudík, J., Vyzula, R. Epidemiologie zhoubných nádorů v České republice. www.svod.cz [ 2011.

15. Foulkes, WD., Brunet, JS., Stefansson, IM., et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004, 64, p. 830-835.

16. Fredholm, H., Eaker, S., Frisell, J., et al. Breast cancer in young women: poor survival despite intensive treatment. PLoS.One, 2009, 4, p. e7695.

17. Gajdos, C., Tartter, PI., Bleiweiss, IJ., et al. Stage 0 to stage III breast cancer in young women. J Am Coll Surg, 2000, 190, p. 523-529.

18. Gonzalez-Angulo, AM., Sahin, A., Krishnamurthy, S., et al. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer, 2006, 7, p. 396‑400.

19. Han, W., Kang, SY. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat, 2010, 119, p. 193-200.

20. Han, W., Kim, SW., Park, IA., et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer, 2004, 4, p. 82.

21. Hankey, BF., Miller, B., Curtis, R., Kosary, C. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr, 1994, p. 7-14.

22. Kolarik, D., Halaska, M., Feyereisl, J. Repetitorium gynekologie. Praha: Maxdorf Jessenius, 2008.

23. Kwong, A., Cheung, P., Chan, S., Lau, S. Breast cancer in Chinese women younger than age 40: are they different from their older counterparts? World J Surg, 2008, 32, p. 2554-2561.

24. Maggard, MA., O’Connell, JB., Lane, KE., et al. Do young breast cancer patients have worse outcomes? J Surg Res, 2003, 113, p. 109-113.

25. Majek, O., Danes, J., Skovajsova, M., et al. Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health, 2011, 11, p. 288.

26. Mauri, D., Pavlidis, N., Ioannidis, JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst, 2005, 97, p. 188-194.

27. Nixon, AJ., Neuberg, D., Hayes, DF., et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol, 1994, 12, p. 888-894.

28. Rakha, EA., Patel, A., Powe, DG., et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol, 2010, 34, p. 1472‑1479.

29. Ries, LG., Eisner, MP., Kosary, CL., et al. SEER cancer statistics review 1973-1999. Bethesda, MD: National Cancer Institute, 2002.

30. ÚZIS (Národní onkologický registr ČR). Novotvary 2008 ČR. Praha:ÚZIS Zdravotnická statistika, 2011.

31. Winchester, DP., Osteen, RT., Menck, HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer, 1996, 78, p. 1838-1843.

32. Wolmark, N., Wang, J., Mamounas, E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr, 2001, p. 96-102.

33. Yankaskas, BC. Epidemiology of breast cancer in young women. Breast Dis, 2005, 23, p. 3-8.